Of Mice and Men: Predictive Toxicology
This article was originally published in Start Up
Current in vivo and in vitro models can't keep up with the demand for the safety assessment of large numbers of compounds emerging from high-throughput strategies. Pharmaceutical companies and start-ups are therefore building new systems that they hope will be capable of predicting the toxicity liabilities of new compounds. Cheminformatics can help week out toxic compounds at the lead selection and optimization stage; toxicogenomics may provide a toxicity diagnostic capability at all stages of drug development. For both toxicology approaches, there is not yet enough high quality data to build predictive models. Toxicology-focused cheminformatics programs attempt to consolidate data from hitherto untapped sources; toxicogenomics companies are engaged in the fussy and expensive process of manufacturing data from scratch and validating them with biological experiments.
You may also be interested in...
ADMETRx is building new and improved ADME tools. The technology, a mix of wet lab analysis and computer modeling, attempts to move beyond the go/no go decisions typical of ADME.Instead the company offers clients a ranking of a drugs being tested based on the individual properties being tested.
Ask a head of R&D for a pharma or biotech to name the area where the need for new and better tools is greatest, and likely as not the answer will be predictive modeling of a drug's ADME/Tox profile. There's an abundance of sweet spots across the preclinical landscape for companies with better models and predictive tools.
Unlike for other tissues and organs in the body, no good cell culture model of the liver exists. This difficulty has hampered the discovery of therapeutics for a wide variety of liver diseases-hepatitis, cancer, and cirrhosis, for example-but Hepaticus Inc. is planning to change this: the firm has devised a way to model human liver cell functionality using immunocompetent rats.